Revolution Medicines to Participate in the 43rd Annual Goldman Sachs Global Healthcare Conference

Rhea-AI Summary

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on therapies for RAS-addicted cancers, will participate in the 43rd Annual Goldman Sachs Global Healthcare Conference from June 13-16, 2022. CEO Mark A. Goldsmith will host a live fireside chat on June 15, 2022, at 1:20 p.m. Pacific Time. Investors can access the live webcast at here, with an archived replay available for 14 days post-event.

REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43^rd Annual Goldman Sachs Global Healthcare Conference. Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines, will be the featured participant in a live fireside chat at the event.

Details of the company’s participation are as follows:

• Conference Date: June 13 – 16, 2022
• Fireside Chat Details: 1:20 p.m. Pacific on Wednesday, June 15, 2022

A live webcast of the fireside chat can be accessed at: https://ir.revmed.com/events-and-presentations. An archived replay of the webcast will be available on the investors section of the company’s website for at least 14 days following the event.

About Revolution Medicines, Inc.

Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. RAS(ON) Inhibitors in development include RMC-6236 (RAS^MULTI), RMC-6291(KRAS^G12C), RMC-9805 (KRAS^G12D) and RMC-8839 (KRAS^G13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).

FAQ

When is Revolution Medicines participating in the Goldman Sachs Global Healthcare Conference?

Revolution Medicines will participate in the Goldman Sachs Global Healthcare Conference from June 13-16, 2022.

What time will the fireside chat with Revolution Medicines CEO take place?

The fireside chat with CEO Mark A. Goldsmith will occur on June 15, 2022, at 1:20 p.m. Pacific Time.

Where can I watch the Revolution Medicines fireside chat live?

You can watch the live fireside chat on the company's investor relations website.

Is there a replay available for the Revolution Medicines fireside chat?

Yes, an archived replay of the fireside chat will be available for at least 14 days following the event.

What types of therapies does Revolution Medicines develop?

Revolution Medicines develops targeted therapies for RAS-addicted cancers, including RAS(ON) Inhibitors and RAS Companion Inhibitors.